In May 2023, Canada became the first G7 country to approve generic versions of semaglutide injections, which are used for treating type 2 diabetes and for weight loss. This approval was significant as it aimed to make these medications more accessible to Canadians, particularly those who had previously found the costs prohibitive. The generics were introduced by two manufacturers: Dr Reddy's from India and Apotex, a Canadian company. The approval of these generics has already led to a decrease in the prices of brand-name drugs like Wegovy, which is also a semaglutide product. Patients in Canada, such as Elizabeth Doran, have expressed relief at the reduced costs, allowing them to maintain their health without financial strain. In contrast, the situation in the United States remains challenging. Ozempic, the brand-name version of semaglutide, can cost uninsured patients over $1,000 per month. The high prices have limited access to these essential medications, particularly for those who need them to manage diabetes. Experts have noted that the lack of affordable alternatives in the US is largely due to stringent patent laws that protect pharmaceutical companies' monopolies for extended periods. This has resulted in a healthcare landscape where only wealthier individuals can afford these life-saving drugs, leaving many patients without necessary treatment options. The approval of generics in Canada has sparked discussions about the potential for similar products to enter the US market. Erez Israeli, CEO of Dr Reddy's, mentioned that his company is seeking approval in over 80 countries, including the US. However, the timeline for availability in the US remains uncertain, as the patent for Ozempic could have been extended until 2028, but Novo Nordisk did not renew it. This situation highlights the complexities of the pharmaceutical industry and the challenges faced by patients in accessing affordable medications. The introduction of generics in Canada is seen as a significant step towards improving healthcare access, but it also raises questions about the future of drug pricing and availability in the US. The disparity between the two countries underscores the need for reform in the US patent system, which many experts argue is necessary to ensure that all patients can access the medications they need without facing financial hardship.